Document is current
Any future updates will be listed below
-
Authors
Lynch, Megan T.
Maloney, Kristin A.
Xu, Huichun
Perry, James A.
Center, Regeneron Genetics
Shuldiner, Alan R.
Mitchell, Braxton D.
-
Funding
Funding for this research was provided by:
University of Maryland School of Medicine Program for Personalized and Genomic Medicine
Regeneron Pharmaceuticals
- License Information
-
More Information
Article History
Received: 1 September 2022
Accepted: 24 February 2023
First Online: 20 March 2023
Declarations
:
: Alle methods were carried out in accordance with relevant guidelines and regulations. All experiments were performed in accordance with university guidelines for human research and the study was approved by the Institutional Review Board of the University of Maryland School of Medicine. Informed consent was obtained from all subjects.
: Not applicable.
: Megan T. Lynch, Kristin A. Maloney, Huichun Xu, James A. Perry, and Braxton D. Mitchell declare that they have no conflict of interest. Alan R. Shuldiner is an employee of Regeneron Pharmaceuticals, Inc. and receives compensation as salary and stock options. The Regeneron Genetics Center is a subsidiary of Regeneron Pharmaceuticals, Inc.
